TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME COMBINED WITH RENAL DYSFUNCTION
Abstract
This review focuses on the analysis of features of the treatment of acute coronary syndrome in patients with renal dysfunction.
Keywords:
acute coronary syndrome, chronic kidney disease.References
1. M. J. Sarnak, A. S. Levey, A. C. Schoolwertр et al. Kidney Disease as a Risk Factor for Development of Cardio-vascular Disease: A Statement From the American Heart As-sociation Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiol-ogy and Prevention. Circulation 2003; 42 (5): 1050-1065.
2. Kidney Disease: Improving Global Outcomes (KDI-GO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney In-ternational Supplements 2013; 3 (5): 259-305.
3. Г. Арутюнов, Т. Чернявская. Проблемы нефропротекции у пациентов с артериальной гипертонией. Значение показателя микроальбуминурии для врача общей практики. Артериальная гипертония 2005; 3: 2-7.
4. О. Кузьмин. Хроническая болезнь почек и состояние сердечно-сосудистой системы. Нефрология 2007; 11 (1): 28-29.
5. Е. Макеева, А. Шутов, В. Серов и др. Хроническая болезнь почек влияет на прогноз и стоимость стационарного лечения больных с хронической сердечной недостаточностью. Нефрология 2010; 14 (2): 21-55.
6. S. Spilner, S. Inverso, M. Cohen et al. Safety and ef-ficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. American Heart Journal 2003; 146 (1): 33-41.
7. J. Januzzi, C. Cannon, P. DiBattiste et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). The American Journal of Cardiology 2002; 90 (11): 1246-1249.
8. C. Gibson, R. Dumaine, E. Gelfand et al. Associa-tion of glomerular filtration rate on presentation with subse-quent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials. European Heart Journal 2004; 25 (22): 1998-2005.
9. C. Gibson, D. Pinto, S. Murphy et al. Association of creatinine clearance on presentation in acute myocardial in-farction with subsequent mortality. Journal of the American College of Cardiology 2003; 42 (9): 1535-1543.
10. F. Rodrigues, R. Bruetto, U. Torres et al. Effects of kidney disease on acute coronary syndrome. Clinical Journal of the Society Nephrology 2010; 5 (8): 1530-1536.
11. Ronco C. Cardiorenal syndromes: definition and classification. Contributions to Nephrology 2010; 164: 33-38.
12. Kidney Disease: Improving Global Outcomes (KDI-GO) CKD Work Group. KDIGO 2012 Clinical Practice Guide-line for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements 2013; 3 (5):1-150.
13. D. Hasdai, S. Behar, L. Wallentin et al. A prospec-tive survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: the Euro Heart Survey of Acute Coro-nary Syndromes. European Heart Journal 2002; 23 (15): 1190-1201.
14. I. Goldenberg, I. Subirana, V. Boyko et al. Relation between renal function and outcomes in patients with non-ST segment elevation acute coronary syndrome: real-world data from the European Public Health Outcome ResearchandIndi-cators Collection Project. Archives of Internal Medicine 2010; 170 (10): 888-895.
15. B. Franczyk-Skóra, A. Gluba, M. Banach et al. Pre-vention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrology 2012; 13: 162.
16. Ю. Вялкина, С. Шалаев. Клиренс креатинина в долгосрочном прогнозировании риска сердечно-сосудистой смерти у больных острым коронарным синдромом без подъемов сегмента ST. Клиническая нефрология 2011; 2: 27-30.
17. W. Couser, M. Riella. World Kidney Day 2011 – Pro-tect your kidneys, save your heart. Archives of Medical Science 2011; 7 (1): 1-4.
18. R. van Domburg, S. Hoeks, G. Welten, et al. Renal insufficiency and mortality in patients with known or suspected coronary artery disease. Journal of the American Society of Nephrology 2008; 19 (1): 158-163.
19. J. Malyszko, H. Bachorzewska-Gajewska, J. Maly-szko, et al. Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular fil-tration rate. Archives of Medical Science 2011; 7 (4): 658-664.
20. Н. Мухин, Г. Арутюнов, В. Фомин. Альбуминурия – маркер поражения почек и риска сердечно-сосудистых осложнений. Клиническая нефрология 2009; 1: 5–10.
21. D. Nair, S. Mehta, D. Mikhailidis. Assessing renal function – searching for the perfect marker continues! Ar-chives of Medical Science 2011; 7 (4): 565-567.
22. W. Coats, S. Baig, M. Alpert, K. Aggarwal. Manage-ment of coronary artery disease in patients with chronic kidney disease. Advances in Peritoneal Dialysis 2009; 25: 125-128.
23. J. Collet, G. Montalescot, G. Agnelli et al. Non-ST segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. European Heart Journal 2005; 26 (21): 2285-2293.
24. S. James, A. Budaj, P. Aylward et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition andPatient Outcomes (PLATO) trial. Circulation 2010; 122 (11):1056-1067.
25. M. Kowalczyk, M. Banach, D. Mikhailidis et al. Ti-cagrelor: a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibi-tors? Medical Science Monitor 2009; 15 (12): MS24-30.
26. P. J. Best, S. R. Steinhubl, P. B. Berger et al. The ef-ficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney dis-ease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 2008; 155 (4): 687-693.
27. B. Franczyk-Skóra, A. Gluba, M. Banach et al. Acute coronary syndromes in patients with chronic kidney disease. Current Vascular Pharmacology 2013; 11 (5): 758-767.
28. C. Hamm, J. Bassand, S. Agewall et al. ESC Com-mittee for Practice Guidelines. ESC Guidelines for the man-agement of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society ofCardiology (ESC). European Heart Journal 2011; 32 (23): 2999-3054.
29. Н. А. Мухин. Снижение скорости клубочковой фильтрации — общепопуляционный маркер неблагоприятного прогноза. Терапевтический архив 2007; 6: 5-10.
30. C. R. Swanepoel. Chronic kidney disease is a risk factor for cardiovascular disease. SA Heart Journal 2007; 4 (3): 38-43.
31. A. Mercando, H. Lai, W. Aronow et al. Reduction in atherosclerotic events: a retrospective study in an outpatient cardiology practice. Archives of Medical Science 2012; 8 (1): 57-62.
32. K. Szummer, P. Lundman, S. Jacobson et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. Journal of Internal Medicine 2010. 268 (1); 40–49.
33. C. Fox, P. Muntner, A. Chen et al. Acute Coronary Treatment and Intervention Outcomes Network registry. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network reg-istry. Circulation 2010; 121 (3): 357-365.
34. J. Rhee, S. Wiviott, B. Scirica et al. Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Out-comes Among Patients With Chronic Kidney Disease Follow-ing Non–ST-Elevation Acute Coronary Syndrome. Clinical Cardiology 2014; 37 (6): 350-356.
35. C. Medi, G. Montalescot, A. Budaj et al. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Glob-al Registry of Acute Coronary Events). JACC: Cardiovascular Intervention 2009; 2 (1): 26-33.
36. C. Meisinger, A. Doring, H. Lowel. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women form the general population. European Heart Journal 2006; 27 (10): 1245–1250.
37. L. Szczech, P. Best, E. Crowley et al. Outcomes of patients with chronic renal insufficiency in the bypass angio-plasty revascularization investigation. Circulation 2002; 105 (19): 2253– 2258.
38. P. McCullough, S. Soman, S. Shah et al. Risks associ-ated with renal dysfunction in patients in the coronary care unit. Journal of the American College of Cardiology 2000; 36 (3):679–684.
39. J. Beattie, S. Soman, K. Sandberg et al. Determinants of mortality after myocardial infarction in patients with ad-vanced renal dysfunction. American Journal of Kidney Diseases 2001; 37 (6): 1191–1200.
40. S. Coca, H. Krumholz, A. Garg et al. Underrepresen-tation of renal disease in randomized controlled trials of car-diovascular disease. JAMA 2006; 296 (11):1377– 1384.
41. А. Николаев, В. Ермоленко. Место блокаторов РАС в нефропротективной стратегии при хронической болезни почек. Нефрология и диализ 2012; 12 (1): 8-12.
42. H. Lai, W. Aronow, A. Mercando et al. Risk factor re-duction in progression of angiographic coronary artery dis-ease. Archives of Medical Science 2012; 8 (3): 444-448.
43. R. Wright, G. Reeder, C. Herzog et al. Acute myocar-dial infarction and renal dysfunction: a high-risk combination. Annals of Internal Medicine 2002; 137 (7): 563-570.
44. C. Baigent, M. Landray, C. Leaper et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. American Journal of Kidney Diseases 2005; 45 (3): 473-484.
45. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarc-tion, and stroke in high risk patients. British Medical Journal 2002; 324 (7329): 71-86.
46. A. Berger, S. Duval, H. Krumholz. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acutemyocar-dial infarction. Journal of the American College of Cardiology 2003; 42 (2): 201-208.
47. A. Sciahbasi, R. Arcieri, M. Quarto et al. Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. Preventive Cardiology 2010; 13 (1): 18-22.
48. D. Reddan, J. O’Shea, I. Sarembock et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). American Journal of Cardiology 2003; 91 (1): 17-21.
49. R. Freeman, R. Mehta, W. Al Badr et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of gly-coprotein IIb/IIIa inhibitors. Journal of the American College of Cardiology 2003; 41 (5): 718-724.
50. P. Berger, P. Best, E. Topol et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. American Heart Journal 2005; 149 (5): 869-875.
51. A. Kirtane, G. Piazza, S. Murphy et al. Correlates of bleeding events among moderate- to high-risk patients under-going percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI- 30 trial. Journal of the American College of Cardiology 2006; 47 (12): 2374-2379.
52. K. Alexander, A. Chen, M. Roe et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294 (24): 3108-3116.
53. S. Basra, P. Tsai, N. Lakkis. Antiplatelet and anti-thrombotic therapy in ACS patients with CKD: antiplatelet and antithrombotic drugs. Journal of the American College of Cardiology 2011; 58 (22): 2263-2269.
54. C. Torp-Pedersen, L. Kober. Effects of ACE inhibitor trandolapril on life expectancy of patients with reduced LVEF after acute myocardial infarction. TRACE Study Group. Tran-dolapril Cardiac Evaluation. Lancet 1999; 354 (9172): 9-12.
55. G. Dagenais, J. Pogue, K. Fox et al. Angiotensin-con-verting enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trial. Lancet 2006; 368 (9535): 581-588.
56. J. Mann, H. Gerstein, J. Pogue et al. Renal insuffi-ciency as a predictor of cardiovascular outcomes and the im-pact of ramipril: the HOPE randomized trial. Annals of Inter-nal Medicine 2001; 134(8): 629-636.
57. ONTARGET Investigators, S. Yusuf, K. Teo, J. Pogue et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England Journal of Medicine 2008; 358 (15): 1547-1559.
58. J. Lopez-Sendon, K. Swedberg, J. McMurray et al. Expert consensus document on beta-adrenergic receptor blockers. European Heart Journal 2004; 25 (15): 1341-1362.
59. M. Stepien, M. Banach, D. Mikhailidis et al. Role and significance of statins in the treatment of hypertensive patients. Current Medical Research and Opinion 2009; 25 (8): 1995-2005.
60. C. Cannon, E. Braunwald, C. McCabe et al. Intensive versus moderate lipid lowering with statins after acute coro-nary syndromes. The New England Journal of Medicine 2004; 350 (15): 1495-1504.
61. N. Edwards, R. Steeds, C. Ferro et al. The treatment of coronary artery disease in patients with chronic kidney dis-ease. QJM 2006; 99 (11): 723-736.
62. V. Athyros, A. Hatzitolios, A. Karagiannis et al.; IM-PERATIVE Collaborative Group. IMproving the imPlemEnta-tion of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial intervention. The IMPERATIVE renal analysis. Archives of Medical Science 2011; 7 (6): 984-992.
63. M. Munar, H. Singh Drug dosing adjustments in pa-tients with chronic kidney disease. American Family Physician 2007; 75 (10):1487-1496.
R. Scarpioni, M. Ricardi, V. Albertazzi et al. Treat-ment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins. World Journal of Nephology 2012; 1 (6):184-194.
65. В. Моисеев, Н. Мухин, Ж. Кобалава и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клиническая нефрология 2014; 2: 4-29.
66. B. Franczyk-Skóra, A. Gluba, M. Banach et al. Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. Archives of Medical Science 2013; 9 (6): 1019-1027.
67. G. Marenzi, A. Cabiati, E. Assanelli. Chronic kidney disease in acute coronary syndromes. World Journal of Nephrology 2012; 1 (5): 134-145.
